Core Insights - The current period is characterized as a pivotal evolution with a significantly lowered risk profile following the ANNAFILM Complete Response Letter (CRL) [1] Financial Performance - The company experienced a 10% revenue increase in manufacturing and supply, particularly from Suboxone and ONDEEF, despite a slight full-year decline due to prior-year one-time deferred revenue recognition [1] Regulatory and Strategic Developments - The company rapidly addressed CRL requirements within 31 days by contracting CROs, modifying packaging for easier opening, and finalizing protocols for human factors and PK studies [1] - Strategic positioning has shifted to prioritize ANNAFILM as the primary growth driver, leading to the decision to out-license Libervant in the U.S. to focus resources on the epinephrine launch [1] Team Enhancements - The clinical team was significantly strengthened with the addition of renowned allergist Dr. Matt Greenhawk and seasoned development leader Dr. Matthew Davis to lead FDA interactions [1] Legal and Commercial Strategy - Management settled a nine-year defamation lawsuit, described as a strategic move to remove a long-standing distraction and simplify the company's legal workload [1] - The commercial strategy now includes a 50% increase in the planned sales force, expanding from 50 to 75 representatives to deepen penetration into the allergist and high-decile pediatrician markets [1]